Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma

Yujin Hoshida, Yasushi Shiratori, Masao Omata

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: To evaluate cost-effectiveness of adjuvant interferon therapy used with surgical resection of hepatitis C-related primary hepatocellular carcinoma. Design: We constructed a Markov model that simulated adjuvant interferon therapy after resection of hepatitis C-related hepatocellular carcinoma, and evaluated life expectancy, costs, and cancer recurrence. The reference case is a 60-year-old man with hepatitis C-related compensated cirrhosis. Results: At the baseline, adjuvant interferon therapy yielded 6.1 life years with a cost of $77, 000, and an incremental cost-effectiveness ratios of $ 15, 700/life year compared with no interferon therapy. The proportion of patients who experienced recurrence of hepatocellular carcinoma until death was reduced from 87.6% to 62.9% using adjuvant interferon therapy. The incidence of recurrent hepatocellular carcinoma after interferon influenced the cost-effectiveness of adjuvant interferon therapy. A threshold analysis showed that adjuvant interferon therapy was not cost-effective (ICER = $ 27, 000/year) if the annual incidence of recurrent hepatocellular carcinoma after interferon is 16% (baseline 8.9%). The proportions of patients with recurrent hepatocellular carcinoma were 74.4% and 86.9% at the annual recurrence rates after interferon of 16% and 35%, respectively. Conclusions: Adjuvant interferon therapy after surgical resection of primary hepatitis C-related hepatocellular carcinoma improves life expectancy through suppression of recurrent cancer with acceptable cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)479-485
Number of pages7
JournalLiver
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Hepatitis C
Interferons
Cost-Benefit Analysis
Hepatocellular Carcinoma
Therapeutics
Life Expectancy
Costs and Cost Analysis
Recurrence
Incidence
Neoplasms
Fibrosis

Keywords

  • Cost-effectiveness
  • Cost-effectiveness ratio-inferon
  • Hepatitis C
  • Hepatocellular carcinoma
  • Incremental
  • Interferon
  • Markov model
  • Surgical resection

ASJC Scopus subject areas

  • Hepatology

Cite this

Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma. / Hoshida, Yujin; Shiratori, Yasushi; Omata, Masao.

In: Liver, Vol. 22, No. 6, 01.12.2002, p. 479-485.

Research output: Contribution to journalArticle

@article{87c10b92a542451cadd1dfa6e48002b7,
title = "Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma",
abstract = "Background: To evaluate cost-effectiveness of adjuvant interferon therapy used with surgical resection of hepatitis C-related primary hepatocellular carcinoma. Design: We constructed a Markov model that simulated adjuvant interferon therapy after resection of hepatitis C-related hepatocellular carcinoma, and evaluated life expectancy, costs, and cancer recurrence. The reference case is a 60-year-old man with hepatitis C-related compensated cirrhosis. Results: At the baseline, adjuvant interferon therapy yielded 6.1 life years with a cost of $77, 000, and an incremental cost-effectiveness ratios of $ 15, 700/life year compared with no interferon therapy. The proportion of patients who experienced recurrence of hepatocellular carcinoma until death was reduced from 87.6{\%} to 62.9{\%} using adjuvant interferon therapy. The incidence of recurrent hepatocellular carcinoma after interferon influenced the cost-effectiveness of adjuvant interferon therapy. A threshold analysis showed that adjuvant interferon therapy was not cost-effective (ICER = $ 27, 000/year) if the annual incidence of recurrent hepatocellular carcinoma after interferon is 16{\%} (baseline 8.9{\%}). The proportions of patients with recurrent hepatocellular carcinoma were 74.4{\%} and 86.9{\%} at the annual recurrence rates after interferon of 16{\%} and 35{\%}, respectively. Conclusions: Adjuvant interferon therapy after surgical resection of primary hepatitis C-related hepatocellular carcinoma improves life expectancy through suppression of recurrent cancer with acceptable cost-effectiveness.",
keywords = "Cost-effectiveness, Cost-effectiveness ratio-inferon, Hepatitis C, Hepatocellular carcinoma, Incremental, Interferon, Markov model, Surgical resection",
author = "Yujin Hoshida and Yasushi Shiratori and Masao Omata",
year = "2002",
month = "12",
day = "1",
doi = "10.1034/j.1600-0676.2002.01736.x",
language = "English (US)",
volume = "22",
pages = "479--485",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma

AU - Hoshida, Yujin

AU - Shiratori, Yasushi

AU - Omata, Masao

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Background: To evaluate cost-effectiveness of adjuvant interferon therapy used with surgical resection of hepatitis C-related primary hepatocellular carcinoma. Design: We constructed a Markov model that simulated adjuvant interferon therapy after resection of hepatitis C-related hepatocellular carcinoma, and evaluated life expectancy, costs, and cancer recurrence. The reference case is a 60-year-old man with hepatitis C-related compensated cirrhosis. Results: At the baseline, adjuvant interferon therapy yielded 6.1 life years with a cost of $77, 000, and an incremental cost-effectiveness ratios of $ 15, 700/life year compared with no interferon therapy. The proportion of patients who experienced recurrence of hepatocellular carcinoma until death was reduced from 87.6% to 62.9% using adjuvant interferon therapy. The incidence of recurrent hepatocellular carcinoma after interferon influenced the cost-effectiveness of adjuvant interferon therapy. A threshold analysis showed that adjuvant interferon therapy was not cost-effective (ICER = $ 27, 000/year) if the annual incidence of recurrent hepatocellular carcinoma after interferon is 16% (baseline 8.9%). The proportions of patients with recurrent hepatocellular carcinoma were 74.4% and 86.9% at the annual recurrence rates after interferon of 16% and 35%, respectively. Conclusions: Adjuvant interferon therapy after surgical resection of primary hepatitis C-related hepatocellular carcinoma improves life expectancy through suppression of recurrent cancer with acceptable cost-effectiveness.

AB - Background: To evaluate cost-effectiveness of adjuvant interferon therapy used with surgical resection of hepatitis C-related primary hepatocellular carcinoma. Design: We constructed a Markov model that simulated adjuvant interferon therapy after resection of hepatitis C-related hepatocellular carcinoma, and evaluated life expectancy, costs, and cancer recurrence. The reference case is a 60-year-old man with hepatitis C-related compensated cirrhosis. Results: At the baseline, adjuvant interferon therapy yielded 6.1 life years with a cost of $77, 000, and an incremental cost-effectiveness ratios of $ 15, 700/life year compared with no interferon therapy. The proportion of patients who experienced recurrence of hepatocellular carcinoma until death was reduced from 87.6% to 62.9% using adjuvant interferon therapy. The incidence of recurrent hepatocellular carcinoma after interferon influenced the cost-effectiveness of adjuvant interferon therapy. A threshold analysis showed that adjuvant interferon therapy was not cost-effective (ICER = $ 27, 000/year) if the annual incidence of recurrent hepatocellular carcinoma after interferon is 16% (baseline 8.9%). The proportions of patients with recurrent hepatocellular carcinoma were 74.4% and 86.9% at the annual recurrence rates after interferon of 16% and 35%, respectively. Conclusions: Adjuvant interferon therapy after surgical resection of primary hepatitis C-related hepatocellular carcinoma improves life expectancy through suppression of recurrent cancer with acceptable cost-effectiveness.

KW - Cost-effectiveness

KW - Cost-effectiveness ratio-inferon

KW - Hepatitis C

KW - Hepatocellular carcinoma

KW - Incremental

KW - Interferon

KW - Markov model

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=0036905052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036905052&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0676.2002.01736.x

DO - 10.1034/j.1600-0676.2002.01736.x

M3 - Article

C2 - 12445173

AN - SCOPUS:0036905052

VL - 22

SP - 479

EP - 485

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 6

ER -